In the murine model of Leishmania major infection, resistance or susceptibility to the parasite has been associated with the development of a Th1 or Th2 type of immune response. Recently, however, the immunosuppressive effects of IL-10 have been ascribed a crucial role in the development of the different clinical correlates of Leishmania infection in humans. Since T cells and professional APC are important cellular sources of IL-10, we compared leishmaniasis disease progression in T cell-specific, macrophage/neutrophil-specific and complete IL-10-deficient C57BL/6 as well as T cell-specific and complete IL-10-deficient BALB/c mice. As early as two weeks after infection of these mice with L. major, T cell-specific and complete IL-10-deficient animals showed significantly increased lesion development accompanied by a markedly elevated secretion of IFN-γ or IFN-γ and IL-4 in the lymph nodes draining the lesions of the C57BL/6 or BALB/c mutants, respectively. In contrast, macrophage/neutrophil-specific IL-10-deficient C57BL/6 mice did not show any altered phenotype. During the further course of disease, the T cell-specific as well as the complete IL-10-deficient BALB/c mice were able to control the infection. Furthermore, a dendritic cell-based vaccination against leishmaniasis efficiently suppresses the early secretion of IL-10, thus contributing to the control of parasite spread. Taken together, IL-10 secretion by T cells has an influence on immune activation early after infection and is sufficient to render BALB/c mice susceptible to an uncontrolled Leishmania major infection.
References
[1]
Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366: 1561–1577. doi: 10.1016/s0140-6736(05)67629-5
[2]
Sacks D, Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845–858. doi: 10.1038/nri933
[3]
Peters N, Sacks D (2006) Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunol Rev 213: 159–179. doi: 10.1111/j.1600-065x.2006.00432.x
[4]
Kopf M, Brombacher F, K？hler G, Kienzle G, Widmann KH, et al. (1996) IL-4-deficient BALB/c mice resist infection with Leishmania major. J Exp Med 184: 1127–1136. doi: 10.1084/jem.184.3.1127
[5]
Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, et al. (1990) Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon γ-independent mechanism. J Exp Med 171: 115–127. doi: 10.1084/jem.171.1.115
[6]
Launois P, Maillard I, Pingel S, Swihart KG, Xénarios I, et al. (1997) IL-4 rapidly produced by Vβ4 Vα8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6: 541–549. doi: 10.1016/s1074-7613(00)80342-8
[7]
Noben-Trauth N, Paul WE, Sacks DL (1999) IL-4- and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J Immunol 162: 6132–6140.
[8]
Ji J, Sun J, Soong L (2003) Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis. Infect Immun 71: 4278–4288. doi: 10.1128/iai.71.8.4278-4288.2003
[9]
Jones DE, Buxbaum LU, Scott P (2000) IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J Immunol 165: 364–372. doi: 10.4049/jimmunol.165.1.364
[10]
St？ger S, Alexander J, Carter KC, Brombacher F, Kaye PM (2003) Both interleukin-4 (IL-4) and IL-4 receptor α signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect Immun 71: 4804–4807. doi: 10.1128/iai.71.8.4804-4807.2003
[11]
Kaye PM, Curry AJ, Blackwell JM (1991) Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol 146: 2763–2770.
[12]
Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683–765. doi: 10.1146/annurev.immunol.19.1.683
[13]
Bouabe H, Liu Y, Moser M, B？sl MR, Heesemann J (2011) Novel highly sensitive IL-10-β-lactamase reporter mouse reveals cells of the innate immune system as a substantial source of IL-10 in vivo. J Immunol 187: 3165–3176. doi: 10.4049/jimmunol.1101477
[14]
Hedrich C, Bream J (2010) Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol Res 47: 185–206. doi: 10.1007/s12026-009-8150-5
Jankovic D, Kullberg MC, Feng CG, Goldszmid RS, Collazo CM, et al. (2007) Conventional T-bet+Foxp3？ Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med 204: 273–283. doi: 10.1084/jem.20062175
[17]
Namangala B, No？l W, de Baetselier P, Brys L, Beschin A (2001) Relative contribution of interferon-γ and interleukin-10 to resistance to murine african trypanosomosis. J Infect Dis 183: 1794–1800. doi: 10.1086/320731
[18]
Herbert DBR, Orekov T, Perkins C, Finkelman FD (2008) IL-10 and TGF-β redundantly protect against severe liver injury and mortality during acute schistosomiasis. J Immunol 181: 7214–7220. doi: 10.4049/jimmunol.181.10.7214
[19]
Beiting DP, Gagliardo LF, Hesse M, Bliss SK, Meskill D, et al. (2007) Coordinated control of immunity to muscle stage Trichinella spiralis by IL-10, regulatory T cells, and TGF-β. J Immunol 178: 1039–1047. doi: 10.4049/jimmunol.178.2.1039
[20]
Kane MM, Mosser DM (2001) The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 166: 1141–1147. doi: 10.4049/jimmunol.166.2.1141
[21]
Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, et al. (2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194: 1497–1506. doi: 10.1084/jem.194.10.1497
[22]
Ghalib HW, Piuvezam MR, Skeiky YAW, Siddig M, Hashim FA, et al. (1993) Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92: 324–329. doi: 10.1172/jci116570
[23]
Ismail A, El Hassan AM, Kemp K, Gasim S, Kadaru AEGMY, et al. (1999) Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J Pathol 189: 615–622. doi: 10.1002/(sici)1096-9896(199912)189:4<615::aid-path466>3.0.co;2-z
[24]
Akuffo H, Maasho K, Blostedt M, H？jeberg B, Britton S, et al. (1997) Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin-10 while those from localized leishmaniasis patients induce interferon-gamma. J Infect Dis 175: 737–741. doi: 10.1093/infdis/175.3.737
[25]
St？ger S, Joshi T, Bankoti R (2010) Immune evasive mechanisms contributing to persistent Leishmania donovani infection. Immunol Res 47: 14–24. doi: 10.1007/s12026-009-8135-4
[26]
Ansari NA, Kumar R, Gautam S, Nylén S, Singh OP, et al. (2011) IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol 186: 3977–3985. doi: 10.4049/jimmunol.1003588
[27]
Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502–507. doi: 10.1038/nature01152
[28]
Mendez S, Reckling SK, Piccirillo CA, Sacks D, Belkaid Y (2004) Role for CD4+ CD25+ regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J Exp Med 200: 201–210. doi: 10.1084/jem.20040298
[29]
Anderson CF, Oukka M, Kuchroo VJ, Sacks D (2007) CD4+CD25？Foxp3？ Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 204: 285–297. doi: 10.1084/jem.20061886
[30]
St？ger S, Maroof A, Zubairi S, Sanos SL, Kopf M, et al. (2006) Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10+ CD4+ T cells. Eur J Immunol 36: 1764–1771. doi: 10.1002/eji.200635937
[31]
Groux H, Cottrez F, Rouleau M, Mauze S, Antonenko S, et al. (1999) A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol 162: 1723–1729.
[32]
Ronet C, Torre YH-L, Revaz-Breton M, Mastelic B, Tacchini-Cottier F, et al. (2010) Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production. J Immunol 184: 886–894. doi: 10.4049/jimmunol.0901114
[33]
Roers A, Siewe L, Strittmatter E, Deckert M, Schlüter D, et al. (2004) T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med 200: 1289–1297. doi: 10.1084/jem.20041789
[34]
Siewe L, Bollati-Fogolin M, Wickenhauser C, Krieg T, Müller W, et al. (2006) Interleukin-10 derived from macrophages and/or neutrophils regulates the inflammatory response to LPS but not the response to CpG DNA. Eur J Immunol 36: 3248–3255. doi: 10.1002/eji.200636012
[35]
Flohé SB, Bauer C, Flohé S, Moll H (1998) Antigen-pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major. Eur J Immunol 28: 3800–3811. doi: 10.1002/(sici)1521-4141(199811)28:11<3800::aid-immu3800>3.3.co;2-s
[36]
Ramírez-Pineda JR, Fr？hlich A, Berberich C, Moll H (2004) Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J Immunol 172: 6281–6289. doi: 10.4049/jimmunol.172.10.6281
[37]
Noben-Trauth N, Lira R, Nagase H, Paul WE, Sacks DL (2003) The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J Immunol 170: 5152–5158. doi: 10.4049/jimmunol.170.10.5152
[38]
Schwenk F, Baron U, Rajewsky K (1995) A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res 23: 5080–5081. doi: 10.1093/nar/23.24.5080
[39]
Salhi A, Rodrigues V Jr, Santoro F, Dessein H, Romano A, et al. (2008) Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol 180: 6139–6148. doi: 10.4049/jimmunol.180.9.6139
[40]
Nylén S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, et al. (2007) Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 204: 805–817. doi: 10.1084/jem.20061141
[41]
Darrah PA, Patel DT, De Luca PM, Lindsay RWB, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843–850. doi: 10.1038/nm1592
[42]
Remer KA, Apetrei C, Schwarz T, Linden C, Moll H (2007) Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice. Eur J Immunol 37: 2463–2473. doi: 10.1002/eji.200636780
[43]
Couper KN, Blount DG, Riley EM (2008) IL-10: the master regulator of immunity to infection. J Immunol 180: 5771–5777. doi: 10.4049/jimmunol.180.9.5771
[44]
Li MO, Flavell RA (2008) Contextual regulation of inflammation: a duet by transforming growth factor-β and interleukin-10. Immunity 28: 468–476. doi: 10.1016/j.immuni.2008.03.003
[45]
Miles SA, Conrad SM, Alves RG, Jeronimo SMB, Mosser DM (2005) A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 201: 747–754. doi: 10.1084/jem.20041470
[46]
Belkaid Y, von Stebut E, Mendez S, Lira R, Caler E, et al. (2002) CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168: 3992–4000. doi: 10.4049/jimmunol.168.8.3992
[47]
Uzonna JE, Joyce KL, Scott P (2004) Low dose Leishmania major promotes a transient T helper cell type 2 response that is down-regulated by interferon γ-producing CD8+ T cells. J Exp Med 199: 1559–1566. doi: 10.1084/jem.20040172
[48]
Huber M, Timms E, Mak TW, R？llinghoff M, Lohoff M (1998) Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice. Infect Immun 66: 3968–3970.
[49]
Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, et al. (1991) IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146: 3444–3451.
[50]
Peters NC, Bertholet S, Lawyer PG, Charmoy M, Romano A, et al. (2012) Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice. J Immunol 189: 4832–4841. doi: 10.4049/jimmunol.1201676
[51]
Aseffa A, Gumy A, Launois P, MacDonald HR, Louis JA, et al. (2002) The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells. J Immunol 169: 3232–3241. doi: 10.4049/jimmunol.169.6.3232
[52]
Xu D, Liu H, Komai-Koma M, Campbell C, McSharry C, et al. (2003) CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J Immunol 170: 394–399. doi: 10.4049/jimmunol.170.1.394
[53]
Chu N, Thomas BN, Patel SR, Buxbaum LU (2010) IgG1 is pathogenic in Leishmania mexicana infection. J Immunol 185: 6939–6946. doi: 10.4049/jimmunol.1002484
[54]
Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, et al. (2008) Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28: 546–558. doi: 10.1016/j.immuni.2008.02.017
[55]
Charmoy M, Megnekou R, Allenbach C, Zweifel C, Perez C, et al. (2007) Leishmania major induces distinct neutrophil phenotypes in mice that are resistant or susceptible to infection. J Leukoc Biol 82: 288–299. doi: 10.1189/jlb.0706440
[56]
Maroof A, Beattie L, Zubairi S, Svensson M, St？ger S, et al. (2008) Posttranscriptional regulation of Il10 gene expression allows natural killer cells to express immunoregulatory function. Immunity 29: 295–305. doi: 10.1016/j.immuni.2008.06.012
[57]
Veras PST, Welby-Borges M, de Santana CD, Nihei J, Cardillo F, et al. (2006) Leishmania amazonensis: participation of regulatory T and B cells in the in vitro priming (PIV) of CBA/J spleen cells susceptible response. Exp Parasitol 113: 201–205. doi: 10.1016/j.exppara.2006.01.008
[58]
Owens BMJ, Beattie L, Moore JWJ, Brown N, Mann JL, et al. (2012) IL-10-producing Th1 cells and disease progression are regulated by distinct CD11c+ cell populations during visceral leishmaniasis. PLoS Pathog 8: e1002827. doi: 10.1371/journal.ppat.1002827
[59]
Stober CB, Lange UG, Roberts MTM, Alcami A, Blackwell JM (2005) IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol 175: 2517–2524. doi: 10.4049/jimmunol.175.4.2517
[60]
Kedzierski L, Curtis JM, Doherty PC, Handman E, Kedzierska K (2008) Decreased IL-10 and IL-13 production and increased CD44hi T cell recruitment contribute to Leishmania major immunity induced by non-persistent parasites. Eur J Immunol 38: 3090–3100. doi: 10.1002/eji.200838423
[61]
Okwor I, Liu D, Beverley SM, Uzonna JE (2009) Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process. Proc Natl Acad Sci U S A 106: 13951–13956. doi: 10.1073/pnas.0905184106
[62]
Darrah PA, Hegde ST, Patel DT, Lindsay RWB, Chen L, et al. (2010) IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med 207: 1421–1433. doi: 10.1084/jem.20092532
[63]
Clausen BE, Burkhardt C, Reith W, Renkawitz R, F？rster I (1999) Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8: 265–277. doi: 10.1023/a:1008942828960
[64]
Lakso M, Pichel JG, Gorman JR, Sauer B, Okamoto Y, et al. (1996) Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci U S A 93: 5860–5865. doi: 10.1073/pnas.93.12.5860
[65]
Titus RG, Marchand M, Boon T, Louis JA (1985) A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 7: 545–555. doi: 10.1111/j.1365-3024.1985.tb00098.x
[66]
Lutz MB, Kukutsch N, Ogilvie ALJ, R？？ner S, Koch F, et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77–92. doi: 10.1016/s0022-1759(98)00204-x
